A nationwide clinical trial is underway for VDPHL01, a new non-hormonal treatment for androgenetic alopecia (male pattern baldness). This treatment aims to restore hair growth without the side effects commonly associated with hormonal options like finasteride. The drug's manufacturer, Veradermics, raised $75 million to fund the trial, which seeks to examine VDPHL01's effectiveness and safety. Dr. Neil Sadick, a dermatologist, emphasizes that current approved treatments can cause unwanted side effects and that VDPHL01 has a distinct formulation with potential advantages over traditional therapies.
"I emphasize non-hormonal because the only FDA-approved oral treatment for pattern hair loss has a hormonal mechanism of action and is associated with potential hormonal side effects like erectile dysfunction, decreased libido and suicidal thoughts," Dr. Neil Sadick told The Post.
"Topical options also often have high discontinuation rates as they can be messy and cumbersome to apply," added Sadick, a clinical professor of dermatology at Weill Cornell Medical College.
"The trial sponsor, Veradermics, is choosing not to disclose additional information about the drug formulation at this time," Sadick said.
"I can tell you that VDPHL01 has a unique profile unlike current FDA-approved treatments, which are associated with cardiac activity and unwanted sexual side effects," he continued.
Collection
[
|
...
]